A 52-year-old man with acute myocardial infarction develops cardiogenic shock with systolic BP 85 mmHg, heart rate 110/min, elevated JVP, and pulmonary edema. Echocardiography shows severely reduced ejection fraction (20%). After adequate oxygenation and mechanical ventilation, which is the drug of choice for initial hemodynamic support?

Explanation

## Initial Hemodynamic Support in Cardiogenic Shock **Key Point:** Dobutamine is the drug of choice for initial hemodynamic support in cardiogenic shock with severely reduced ejection fraction, as it provides potent inotropic support and reduces cardiac filling pressures. ### Why Dobutamine in This Case This patient has classic cardiogenic shock secondary to acute MI with: - Severely reduced EF (20%) — primary pump failure - Pulmonary edema — elevated left-sided filling pressures - Elevated JVP — elevated right-sided pressures - Hypotension (SBP 85 mmHg) with tachycardia The dominant pathophysiology is **pump failure with low cardiac output**, not peripheral vasodilation. The primary therapeutic goal is to improve myocardial contractility and cardiac output. ### Mechanism of Action of Dobutamine Dobutamine is a synthetic catecholamine with predominantly **β₁-adrenergic** agonist activity: - **Positive inotropy:** Increases myocardial contractility → increases stroke volume and cardiac output - **Mild β₂ effect:** Modest reduction in systemic vascular resistance (afterload reduction) — beneficial in pump failure - **Mild chronotropy:** Less arrhythmogenic than dopamine at equivalent doses - **Reduces PCWP:** Decreases pulmonary congestion — directly addresses pulmonary edema in this patient ### Comparison of Agents | Feature | Dobutamine | Dopamine | Noradrenaline | Hydralazine | |---------|-----------|----------|---------------|-------------| | **Primary effect** | Inotropy (β₁) | Dose-dependent | Vasoconstriction (α) | Vasodilation | | **Cardiac output** | ✓✓ Increases | ✓ Increases | ✗ May decrease | ✗ | | **Pulmonary edema** | ✓ Reduces PCWP | ✗ | ✗ | ✗ | | **Arrhythmia risk** | Lower | **Higher** | Low | N/A | | **Use in cardiogenic shock** | **First-line** | Second-line | Refractory/vasodilatory | Contraindicated | ### Why Not the Other Options? - **Dopamine:** Although historically taught as first-line, current evidence (SOAP II trial, Harrison's 21e) shows dopamine has significantly **higher arrhythmia risk** (atrial fibrillation, ventricular arrhythmias) compared to dobutamine/noradrenaline. In a patient already tachycardic at 110/min post-MI, dopamine's chronotropic effects are harmful. Current ACC/AHA and ESC guidelines no longer recommend dopamine as first-line in cardiogenic shock. - **Noradrenaline:** Primarily a vasopressor (α-dominant). While useful in vasodilatory or refractory shock, it increases afterload without improving contractility — potentially worsening pump failure in a patient with EF of 20%. Reserved for refractory cardiogenic shock or when MAP cannot be maintained despite dobutamine. - **Hydralazine:** A pure arterial vasodilator — **absolutely contraindicated** in hypotensive cardiogenic shock. Would precipitously worsen hypotension and organ perfusion. **Clinical Pearl:** Per Harrison's Principles of Internal Medicine (21e, Ch. 297) and current ESC/ACC guidelines, **dobutamine** is the preferred inotropic agent for cardiogenic shock with reduced EF and pulmonary congestion. If MAP remains critically low despite dobutamine, noradrenaline may be added as a vasopressor. Dopamine is no longer first-line due to its arrhythmogenic profile. **High-Yield for NEET PG:** In cardiogenic shock with pulmonary edema and severely reduced EF → **Dobutamine** (inotropy + reduces filling pressures). In refractory shock or when vasopressor is needed → add Noradrenaline. [cite: Harrison 21e Ch. 297; ESC Guidelines on Acute Heart Failure 2021; SOAP II Trial, NEJM 2010]